−0.09GBP
−2.60 MGBP
2.90 MGBP
79.84 M
About FUSION ANTIBODIES PLC ORD GBP0.04
Sector
Industry
CEO
Adrian Kinkaid
Website
Headquarters
Belfast
Founded
2000
ISIN
GB00BDQZGK16
FIGI
BBG00JDYBTZ5
Fusion Antibodies Plc engages in research, development, and manufacturing recombinant proteins and antibodies, particularly in the areas of cancer and infectious diseases. The firm also offers antibody engineering services for all stages of therapeutic and diagnostic antibody development. The company was founded by Michael Townsley and James Anthony Johnston on November 29, 2000 and is headquartered in Belfast, the United Kingdom.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of FAB is 3.80 GBX — it hasn't changed in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange FUSION ANTIBODIES PLC ORD GBP0.04 stocks are traded under the ticker FAB.
FUSION ANTIBODIES PLC ORD GBP0.04 is going to release the next earnings report on May 29, 2024. Keep track of upcoming events with our Earnings Calendar.
Yes, you can track FUSION ANTIBODIES PLC ORD GBP0.04 financials in yearly and quarterly reports right on TradingView.
Like other stocks, FAB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade FUSION ANTIBODIES PLC ORD GBP0.04 stock right from TradingView charts — choose your broker and connect to your account.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. FUSION ANTIBODIES PLC ORD GBP0.04 EBITDA is −2.78 M GBP, and current EBITDA margin is −84.83%. See more stats in FUSION ANTIBODIES PLC ORD GBP0.04 financial statements.